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Abstract:  
Use of next-generation sequencing technologies to transcriptomics (RNA-seq) for gene 
expression profiling has found widespread application in studying different biological 
conditions including cancers. However, RNA-seq experiments are still small sample size 
experiments due to the cost. Recently, an increased focus has been on meta-analysis methods 
for integrated differential expression analysis for exploration of potential biomarkers. In this 
study, we propose a p-value combination method for meta-analysis of multiple related RNA-
seq studies that accounts for sample size of a study and direction of expression of genes in 
individual studies. In contrast to existing meta-analysis methods for RNA-seq data for 
differential expression analysis, the proposed method does not pre- or post-hoc filter genes that 
have conflicting direction of expression in different studies. Thus, our method has better 
potential for the discovery of differentially expressed genes (DEGs) with potentially 
conflicting differential signals from multiple studies related to disease. In a real data 
application, we demonstrate the use of our proposed method to detect biologically relevant 
DEGs in glioblastoma (GBM), the most aggressive brain cancer. Our approach notably enabled 
the identification of over-expression in GBM compared to healthy controls of the oncogene 
RAD51, which has recently been shown to be a target for inhibition to enhance radiosensitivity 
of GBM cells during treatment. Pathway analysis identified multiple aberrant GBM related 
pathways as well as novel regulators such as TCF7L2 and MAPT as important upstream 
regulators in GBM. 
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Introduction 
RNA sequencing (RNA-seq) technologies are now increasingly considered for whole 
transcriptome gene expression quantification studies as compared to traditional microarray 
technologies due to its high technical reproducibility and greater resolution [1]. Over the last 
decade, it has found widespread application in studying different biological conditions 
including cancers. For instance, sequencing data archived on The Cancer Genome Atlas 
(https://portal.gdc.cancer.gov/) have been used in a number of studies to explore potential 
biomarkers and mechanisms in oncogenesis [2][3]. Despite its advantages and few large RNA-
seq datasets [4][5], RNA-seq experiments are still small sample size experiments because of 
its high cost. This leads to a problem of reduced statistical power in studies such as differential 
expression analysis where thousands of genes are studied at a time but only have tens to 
hundreds of samples. Combination of data or results from multiple independent but related 
studies (referred to as meta-analysis) have been widely used to increase available sample size 
and consequently the statistical power to obtain a precise estimate of gene expression 
differentials [6][7]. In the context of differential expression analysis, several different meta-
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analysis approaches have been proposed for integrating microarray studies [8][9] and some of 
them have later been adapted for RNA-seq data [10][11]. 
 
For microarray gene expression studies, meta-analysis methods can mainly be classified into 
three types based on the combined statistic. First are methods based on effect sizes combination 
in which a combined effect (for instance, strength of differential expression between two 
conditions for a gene) is obtained based on the calculated effect sizes and its variance where 
two possible models namely, fixed and random effects model are used to obtain the combined 
effect [12]. Second are approaches based on integration of p-values obtained from per-study 
analysis into a single combined p-value per gene [13].  Lastly, are approaches based on rank 
combination which are non-parametric and allow for integration of studies based on a statistic 
that can be ordered, e.g., fold change of a gene [14].  However, RNA-seq data are counts data, 
i.e., normalized number of sequenced reads within a certain gene or transcript, unlike the 
microarray data which are continuous, e.g., normalized signal intensity of image [15]. Hence, 
the methods initially proposed for microarray data are not suited to be applied directly to RNA-
seq data in many cases [10]. 
 
In case of RNA-seq data, Poisson or Negative-Binomial distributions are typically used to 
model gene counts [16]. Kulinskaya et al. (2008) [17] described an effect-size combination 
method using an Anscombe transformation of Poisson distributed data. However, as 
highlighted by Rau et al. (2014) [10], this effect-size combination approach is not appropriate 
for RNA-seq data due to over-dispersion among biological replicates and presence of zero-
inflation. Rau et al. (2014) considered two p-value combination methods, namely Fisher and 
inverse normal (IN) or Stouffer’s methods, previously proposed and used for meta-analysis of 
microarray studies [8][9][13] and demonstrated how these can be adapted in RNA-seq data 
analysis. In particular, performance of these two p-value combination approaches were 
compared to a global differential analysis with a fixed study effect and no study effect and 
results from per-study differential analysis. Fisher and IN methods were very similar to each 
other in terms of performance but were demonstrated to be better than the other compared 
methods [10]. These two (Fisher and IN) p-value combination approaches have been 
implemented in several R packages, e.g., metaRNASeq [10], metaseqR [18] and metaSeq [19] 
and are most widely used methods for meta-analysis of RNA-seq studies for differential 
expression. Moulos and Hatzis (2015) [18] demonstrated that a performance driven scoring of 
RNA-seq statistics can improve the overall detection of DEGs by false hits reduction while 
maintaining true positives. Ma et al. (2017) [20] proposed a full Bayesian hierarchical model 
(BayesMetaSeq) for RNA-seq meta-analysis which is a one stage approach and advantageous 
for genes with low observed counts. 
  
Among all the existing meta-analysis methods for RNA-seq data discussed above, only few of 
the p-value combination methods (e.g., IN and PANDORA [18]) allows for incorporation of 
information regarding the number of replicates in different studies to be combined through 
specification of a set of weights. However, information related to the direction of expression 
(up- or down-regulated) of a gene across different studies is not accounted for or included in 
any of these meta-analysis methods for RNA-seq data.  Under- and over-expressed genes are 
analysed together and genes exhibiting conflicting direction of expression across studies are 
either removed prior to meta-analysis or are suggested to be identified and removed post-hoc 
[10][11]. Hence, no conclusion can be drawn with regards to differential expression for the 
genes that have conflicting direction of expression across different studies. Given that a 
significant proportion of genes may exhibit conflicting direction of expression across different 
gene expression studies [21], particularly when more and more RNA-seq data are publicly 
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available and included into integration, emphasis is warranted on including this important prior 
information in a meta-analysis setting. 
 
In this study, we aimed to develop a new approach for integrated differential meta-analysis of 
RNA-seq data which accounts for both the sample size and direction of gene regulation in each 
study. First, we propose a modified inverse-normal (MIN) approach for p-value combination 
and assess its performance by comparing it with the IN method based on an extensive 
simulation study. Next, to overcome the conservative nature of MIN method, we further 
propose a fused inverse normal (FIN) method for p-value combination and assess its 
performance by comparing it to IN and MIN methods in a simulation study. Then an 
application to a set of real glioblastoma (GBM, the most aggressive type of brain cancer) 
studies has been conducted. Moreover, we assessed the relevance of the identified differentially 
expressed genes (DEGs) for GBM by using Ingenuity Pathway Analysis (IPA, 
www.qiagen.com/ingenuity) for pathway analysis and upstream regulator analysis. 
 
Methods 
Let 𝑦𝑔𝑐𝑟𝑠 be the observed count for gene 𝑔 (𝑔 = 1, 2, … , 𝐺) in condition 𝑐 (𝑐 = 1, 2) of 
biological replicate 𝑟 (𝑟 = 1, 2, … , 𝑅𝑐𝑠) in study 𝑠 (𝑠 = 1, 2, … , 𝑆). For an integrated 
differential analysis of gene expression across multiple studies, we first conducted the 
differential expression analysis within a given study 𝑠 using edgeR package (version 3.26.5) 
in R version 3.6.0 [22] with likelihood ratio test as the test for differential expression. Let  𝑝𝑔𝑠 
be the raw p-value for per-gene and per-study obtained using the individual differential 
expression analysis within a given study 𝑠 for gene 𝑔. The null hypothesis tested in the 
individual differential analysis is that the gene is non-differentially expressed in the particular 
study. For notational convenience, the notations similar to the ones used in Rau et al. (2014) 
[10] were adopted in this study.  
 
Modified inverse-normal method 
Let 𝐵𝑔𝑠 be a Bernoulli random variable which takes values 1 and -1 when a gene 𝑔 is over and 
under expressed respectively in a study 𝑠. A gene can be assessed as over- or under-expressed 
based on the fold change values (>1 or <1) of the gene in a study. Then, for a gene 𝑔, we define 
a combined statistic   
                                      𝑁𝑔 = ∑ 𝑤𝑠𝐵𝑔𝑠|Φ
−1(1 − 𝑝𝑔𝑠)|
𝑆
𝑠=1                                                   (1) 
where 𝑤𝑠 are a set of study specific weights described by Marot and Mayer [23] as follows: 
                                                     𝑤𝑠 = √
∑ 𝑅𝑐𝑠𝑐
∑ ∑ 𝑅𝑐𝑘𝑐𝑘
                                                                (2) 
Here, ∑ 𝑅𝑐𝑠𝑐  is the total number of biological replicates in a study 𝑠 for all condition c and 
∑ ∑ 𝑅𝑐𝑘𝑐𝑘  indicates the total number of biological replicates in all studies. Moreover, 𝑁𝑔 can 
be considered as a weighted z-score. An advantage of this weighting criteria is that larger 
weights are attributed to studies with larger sample sizes. Φ is the standard normal cumulative 
distribution function and 𝑝𝑔𝑠 is the raw p-value obtained for gene 𝑔 by differential analysis for 
study 𝑠. 
 
It is assumed that 𝑝𝑔𝑠 are uniformly distributed under the null hypothesis and Φ
−1(1 − 𝑝𝑔𝑠) is 
standard normal in the above formula (1), but this assumption of 𝑝𝑔𝑠 is not automatically 
satisfied when dealing with RNA-seq data [10]. However, filtering of very low expressed genes 
in each study results in p-values which are roughly uniformly distributed under the null 
hypothesis [10]. Then, we have that 𝐵𝑔𝑠|Φ
−1(1 − 𝑝𝑔𝑠)| ~ 𝑁(0, 1) (see Theorem 1).  
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Theorem 1: Let 𝑋 and 𝑌 be two independent random variables where 𝑋~𝑁(0, 1) and 𝑌 is a 
Bernoulli random variable taking values 1 and −1. Then, 𝑍 = 𝑌|𝑋| is standard normal 
distributed. 
Proof: Using the first principle,  
ℙ[𝑌|𝑋| ≤ 𝑡 =  ℙ[𝑌 = 1, |𝑋| ≤ 𝑡] + ℙ[𝑌 = −1, −|𝑋| ≤ 𝑡] 
                                                =
1
2
ℙ[|𝑋| ≤ 𝑡] +
1
2
ℙ[|𝑋| ≥ −𝑡]                                             (3) 
Now, if 𝑡 < 0, the RHS of  (3) becomes 
1
2
ℙ[|𝑋| ≥ 𝑡]. By symmetry of the normal distribution, 
we have  
ℙ[𝑌|𝑋| ≤ 𝑡] =  ℙ[𝑋 < 𝑡] = Φ(𝑡) 
where Φ is the cumulative distribution function of standard normal.  
For 𝑡 ≥ 0, the RHS of (3) becomes 
1
2
ℙ[|𝑋| ≤ 𝑡] +
1
2
. Hence, by symmetry of the normal 
distribution, we have  
ℙ[𝑌|𝑋| ≤ 𝑡] = ℙ[𝑋 ∈ [0, 𝑡]] +
1
2
= ℙ[𝑋 ≤ 𝑡] = Φ(𝑡) 
Thus, 𝑍 ∼ 𝑁(0, 1).                                                                                                                  ■ 
Hence, 𝑁𝑔 in equation (1) is a linear combination of independent standard normal variables. 
Thus, is also standard normal.  A two-sided test can then be performed with 𝐻0 being that the 
gene 𝑔 is not differentially expressed between two conditions (case vs control) and combined 
p-value is given by (𝑝𝑔 = ℙ(|𝑧| ≥ 𝑁𝑔), i.e.   
𝑝𝑔 = 2[1 − Φ(|𝑁𝑔|)] 
A correction for multiple testing to control the false discovery rate (FDR) at a desired level 𝛼 
can be done by Benjamini-Hochberg (BH) approach [24].   
 
Simulation study: MIN and IN comparison 
To investigate the performance and compare the MIN method with state-of-the-art p-value 
combination method (IN with post-hoc filtering), we performed a simulation study. An 
extensive set of RNA-seq data was generated using the negative binomial distribution for the 
counts 𝑦𝑔𝑐𝑟𝑠 and method described in Rau et al. (2014) [10] (see Supplementary 1, section: 
Simulation study model). Parameters for the simulation study were estimated from a real RNA-
seq dataset for Alzheimer’s disease (AD) study downloaded from Gene Expression Omnibus 
(GEO, https://www.ncbi.nlm.nih.gov/geo/) [25] with accession number GSE125583 which 
contains data for 219 AD patients and 70 normal control subjects. The method used for 
estimation of mean and dispersion parameters from GSE125583 were as described in Rau et 
al. (2014) with BH p-value < 0.05 being used to classify a gene as a DEG. This dataset was 
chosen as it has considerable number of samples for both biological conditions, namely case 
and control. Simulation settings for inter-study variability parameter (𝜎), number of samples 
per condition and number of studies have been detailed in Table 1. The inter-study variability 
parameter represents the amount of variability between the studies considered for meta-
analysis. In practice, the observed variability between human data studies is considerable 
(𝜎~0.5) [10]. We chose two different values of 𝜎 (0.15 and 0.5) to represent small and large 
amount of inter-study variability respectively.  For each setting described in Table 1, 100 






Table 1. Simulation settings for inter-study variability parameter (𝜎), number of studies and 
number of replicates per study. Area under the ROC curves (AUC) for IN, MIN and FIN 
methods computed using 100 trials for each simulation setting.  
Setting 𝝈 No. of 
studies 
No. of replicates  
(case, control) 
AUC  
(MIN, IN, FIN) 
Std. dev  
(MIN, IN, FIN) 




2 0.15 5 (10, 10) (15, 10) (12, 16) 
(14, 12) (20, 20) 
0.953, 0.970, 
0.970 
0.005, < 0.001, 
0.001 




4 0.5 5 (10, 10) (15, 10) (12, 16) 






For each simulation setting, individual p-values obtained from differential expression analysis 
using edgeR were combined using both MIN and IN methods.  A gene was considered 
differentially expressed if the BH adjusted combined p-value (FDR) < 0.05. Based on area 
under the ROC curves (AUC) (Table 1, Figure 1), both meta-analysis methods performed well 
in terms of detection power in identifying DEGs under all simulation settings. For both low 
(𝜎 = 0.15) and high (𝜎 = 0.5) inter-study variability we observed that the MIN method was 
more conservative (AUC was smaller than IN) than the IN method. However, as the inter-study 
variability and the number of studies to be combined increased, both meta-analysis methods 
were found to have comparable performance (Figure 1c-1d). Although slightly conservative in 
its performance with respect to the IN approach, MIN method has the advantage of using 
direction of expression information leading to identification of DEGs among genes with 
conflicting direction of expression across studies. The conservative behaviour of the MIN 
method can be attributed to the fact that a two-sided hypothesis testing is performed as 
compared to a one-sided test on right-hand tail of the distribution in case of IN method. Hence, 
next we proposed the FIN method as a mixture of IN and MIN methods to circumvent the issue 




Figure 1. Performance comparison of modified inverse-normal, inverse-normal and fused 
inverse-normal methods. Plots of receiver operating characteristics (ROC) curves averaged 
over 100 trials for each simulation setting. Simulation settings are represented by rows (from 
top to bottom): corresponding to low (𝜎 = 0.15) and high (𝜎 = 0.5) inter-study variability and 
columns (from left to right): corresponding to 3 (S=3) and 5 studies (S=5) combined. The red, 
turquoise and magenta ROC curves represent the modified inverse-normal, inverse-normal and 
fused inverse-normal methods respectively. 
 
As expected, with increase in inter-study variability and number of studies to be combined, the 
number of genes with mismatched direction of expression was significantly higher (see 
Supplementary 1: Table 1). We also note that the FDR for all simulation settings was controlled 
well below 5% threshold (Figure 2a). In terms of uniquely identified DEGs by the MIN method 
as compared to IN method, the proportion of true positives (TP) was higher than 80% (Figure 
2b) in all simulation settings. A large proportion of TPs among the unique DEGs identified by 
the MIN method indicates that the MIN approach can lead to DEGs that are biologically 
relevant to a disease in a real application. Moreover, as the inter-study variability, number of 
studies or both increased, there was an increase in the number of uniquely identified DEGs by 
the MIN method and proportion of TPs among them (Figure 2b). More importantly, a high 
percentage of these unique DEGs (>75% in all settings) were observed to have the true 
direction of expression (Figure 2c) suggesting that a significantly high percentage of uniquely 
identified DEGs by the MIN method in real data applications will have true direction of 
expression as their effective direction of expression. The effective observed direction of 




Figure 2. Characteristics of modified inverse-normal method. a). False discovery rates for 
modified inverse-normal method for all simulation settings. b). Proportion of true-positives 
(TPs) among unique differentially expressed genes (DEGs) identified by modified inverse- 
normal (MIN) method as compared to inverse-normal (IN) method. c). Proportion of unique 
DEGs (MIN) with the observed effective direction of expression as the true direction of 
expression. 
Fused inverse-normal method 
To address the conservative nature of MIN method, we propose a mixture method which is a 
mixture of IN and MIN method for integrated differential analysis. Different to formula (1) we 
define 𝑁𝑔 as follows: 









          (4) 
 Here, 𝑤𝑠, Φ and 𝐵𝑔𝑠 have their usual meaning as described previously. As 𝑁𝑔 follows a 
standard normal distribution given the assumption that 𝑝𝑔𝑠 is uniformly distributed under the 
null hypothesis, a one-sided test on the right-hand tail of the distribution (as proposed in [10]) 
can be performed for genes with same direction of expression across studies. For the genes 
with conflicting direction of expression across studies, a two-sided test can be performed. 𝐻0 
being the same in both the cases. Multiple testing correction to control the overall FDR can 
then be carried out using the BH method. A detailed interpretation of the FIN model in terms 
of differential expression of a gene and its direction of expression in individual studies can be 
found in Supplementary 1. 
 
Simulation study: FIN, IN and MIN comparison 
In addition to the simulation study for comparing MIN with IN method, we assess and compare 
the performance of FIN method to that of IN and MIN methods by using the same simulated 
data and settings described in Table 1. Based on AUC (Table 1, Figure 1), FIN performed 
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similar or better than IN method and had better performance than MIN under all simulation 
settings. As with MIN, FIN method also has the advantage of using direction of expression 
information and hence identified DEGs among genes with conflicting direction of expression 
in contrast with IN method. More importantly, we observed that FIN significantly improved 
detection power for true DE genes with concordant differential expression patterns across 
studies as compared to MIN method and does not lead to increased number of false positive 
detections overall (Figure 3a).  
 
As compared to IN, the proportion of TPs among the uniquely identified DEGs by FIN method 
was higher than 90% (Figure 3b) indicating that FIN method can lead to DEGs that are 
biologically relevant to a disease in a real application. Similar to MIN, as the inter-study 
variability, number of studies or both increased, there was an increase in the number of 
uniquely identified DEGs by the FIN method as compared to IN method and proportion of TPs 
among them (Figure 3b). In addition, a high percentage of these unique DEGs (>80% in all 
settings) were observed to have the true direction of expression (Figure 3c) suggesting that a 
significantly high percentage of uniquely identified DEGs by the FIN method in real data 
applications will have true direction of expression as their effective direction of expression. 
The effective observed direction of expression was determined by the sign of 𝑁𝑔 for genes with 
conflicting direction of expression across studies. In case of same direction of expression of a 
gene across studies, the consistent direction of expression was kept as the effective direction 
of expression.   
 
 
Figure 3. Characteristics of fused inverse-normal method. a). False discovery rates for 
fused inverse-normal method for all simulation settings. b). Proportion of true-positives (TPs) 
among unique differentially expressed genes (DEGs) identified by fused inverse-normal (FIN) 
method as compared to inverse-normal (IN) method. c). Proportion of unique DEGs (FIN) with 
the observed effective direction of expression as the true direction of expression. 
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Application to brain cancer data 
To demonstrate how the MIN and FIN method can be adapted in practice for differential meta-
analysis of RNA-seq data and compare it with IN method, an application to real GBM studies 
have been conducted. 
 
Data description 
GBM RNA-seq datasets were searched in GEO (https://www.ncbi.nlm.nih.gov/geo/) and 
TCGA databases (https://portal.gdc.cancer.gov/). Datasets were selected based on a selection 
criterion that at least 3 GBM patients and 3 normal tissue samples are available for analysis. 
Three different GBM RNA-seq datasets, two from GEO (with accession ID: GSE123892 and 
GSE151352) and one from TCGA (TCGA-GBM) matched our selection criteria and were 
considered for analysis (for details, see Table 2). Raw gene or transcript counts data (where 
available) was directly downloaded for TCGA-GBM and GSE123892 datasets. For 
GSE151352, raw FASTQ files were downloaded and processed using Galaxy web platform 
via the European UseGalaxy server (https://usegalaxy.eu/) [26] to obtain raw counts. The 
quality of the raw reads was assessed (using FastQC) and the specified adapter sequence 
ATCACCGACTGCCCATAGAGAGGCTGAGAC was removed with Cutadapt (version 
1.16) [27]. The parameters used for this step were the parameters provided by the submitter of 
the dataset on GEO. The adapter trimmed reads were aligned to the reference genome 
(GRCh37.p13) using sequence aligner RNA STAR (Galaxy version 2.7.5b) [28] where other 
parameters used were default settings. Following alignment, the generated BAM files were 
processed using the featureCounts tool (Galaxy version 1.6.4+galaxy2) to get raw counts for 
each RNA-seq data sample. More details of the processing pipeline used for GSE151352 can 
be found in Supplementary 1: Figure 1. 
 
Table 2. Information about GBM RNA-seq datasets used for integrated analysis using different 
p-value combination methods in our study. Up and down DEGs refer to the up and down-
regulated DEGs obtained in per-study differential analysis. 
Datasets No. of replicates 
(Cases/Normal) 






GSE123892 4/3 15024 1914 1837 
GSE151352 12/12 12916 670 1545 
TCGA-GBM 160/5 17943 3746 3183 
 
Per-study differential expression analysis 
Each of these datasets were processed separately for quality control and differential expression 
analysis using edgeR package (version 3.26.5) in R. Raw counts data (transcript) were 
annotated by mapping Ensembl IDs to Entrez Gene IDs and gene symbols (org.Hs.eg.db 
package, version 3.8.2 in R [29]). Ensembl IDs with no Entrez ID mapping were filtered out. 
For those with multiple matchings, the one with highest aggregated count was selected. Counts 
per million (CPM) threshold was carefully selected to reduce the number of low expressed 
transcripts. We removed a transcript if number of samples equal to or more than the minimum 
number of samples in a condition had less than 0.85 CPM for that transcript. Although 
subjective, this choice of threshold seems to work well for the uniform distribution assumption 
for the p-values under 𝐻0. Only genes left after low expression filtering were considered for 
individual differential expression analysis in order to satisfy the uniformity assumption on p-
values under the null hypothesis (Figure 4a). 
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The remaining transcripts were then normalized using the TMM method [30].  Common and 
tag-wise dispersion were estimated and a negative-binomial generalized log-linear model was 
fitted to the read counts using the glmFit function under the edgeR package. Raw p-values were 
then obtained from the differential analysis for case/control conditions. More information about 
the DEGs identified in per-study differential analysis based on the criteria |log2 𝐹𝐶| > 1 and 
FDR p-value < 0.05 can be found in Table 2. We note that TCGA-GBM dataset has a much 
larger library size (~ 47 million reads, Illumina HiSeq 2000 v2 sequencer) as compared to 
GSE151352 (~ 4 million reads, Ion Torrent S5 sequencer) and GSE123892 (~ 35 million reads, 
Illumina HiSeq 2500 sequencer). Hence, we observed a differing number of genes left after 
filtering and consequently a much larger number of DEGs being observed for TCGA-GBM 
dataset as compared to the other two (Table 2) [31] in per-study differential expression 
analysis. As the sequencing output gets larger, the smaller count differences between samples 
are declared significant by models for differential expression in edgeR. A more detailed 
treatment of differential expression in RNA-seq data and how it is affected by sequencing depth 
and other factors can be found in Tarazona et al. (2011) [31]. 
 
 
Figure 4. Comparison of results from meta-analysis methods. a). Histograms of raw p-
values obtained from per-study differential analysis of GSE123892 and GSE151352 GBM 
datasets from gene expression omnibus used in real data application. b). Venn diagram of the 
differentially expressed genes identified using inverse-normal (IN DEGs), modified inverse-
normal (MIN DEGs) and fused inverse-normal (FIN DEGs) methods.  
Moreover, we also considered individual differential analysis for TCGA-GBM RNA-seq data 
by randomly selecting 20 cases together with available 5 normal samples in order to make all 
three datasets (GSE123892, GSE151352 and TCGA-GBM) comparable in terms of number of 
replicates for the meta-analysis (see Supplementary 1: Table 2). Hence, we considered two 
different meta-analysis scenarios.  
 
Meta-analysis 
Once the raw p-values were obtained from the individual differential expression analysis for 
each dataset, IN, MIN and FIN methods were then applied for p-value combination. Since the 
TCGA-GBM dataset (160 GBM vs 5 normal samples) is much larger in terms of number of 
samples as compared to GSE123892 (4 GBM vs 3 normal samples) and GSE151352 (12 GBM 
vs 12 normal samples), we considered two different combination scenarios. First, all TCGA-
GBM samples were used for individual analysis to obtain the raw p-values. Second, 20 cases 
and 5 normal samples randomly selected from TCGA-GBM dataset were considered for 
individual analysis to get raw p-values and then considered for meta-analysis with the other 
two datasets (GSE123892 and GSE151352). 10 different random selections were made and 
individual differential expression analysis were conducted respectively. Second scenario 
ensured that the datasets included in meta-analysis had comparable sample sizes.  
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In scenario one, a total of 18325 unique gene pool was considered for meta-analysis which was 
the combination of genes identified in each RNA-seq data analysis after quality control and 
filtering (Table 2). 13056 out of 18325 genes (~71%) were found to have the same direction of 
expression across the studies in which they were present whereas 5259 (~29%) of genes had 
conflicting or mismatched direction of expression. The direction of expression for a gene in an 
individual study was determined based on the sign of log2 𝐹𝐶 obtained for that gene in per-
study differential analysis. Hence, only 13056 genes were effectively considered for IN method 
as compared to 18325 genes for MIN and FIN methods for identifying DEGs because of post-
hoc removal of DEGs with conflicting direction of expression in the IN method.  
 
For each of the combination methods, we assessed the number of DEGs based on average 
absolute log fold-change  ∑ |log2 𝐹𝐶𝑖|/𝑛
𝑛
𝑖=1 > 1 and FDR p-value < 0.05 criteria. Here, 
𝑛 denotes the number of datasets in which a particular gene was present. In case a gene was 
absent in a dataset, the weights in the combination methods were estimated only using the 
number of replicates in datasets in which the gene was present. The three p-value combination 
methods were then compared based on number of DEGs identified and unique DEGs identified 
by each method. A total of 5918, 5892 and 6138 DEGs were identified by the IN, MIN and 
FIN methods respectively. Of the DEGs detected by all these meta-analysis methods, more 
than 90% of them were in common (Figure 4b) with FIN method having a higher detection 
power than the other two methods. Moreover, MIN and FIN method identified a total of 233 
and 235 DEGs with mismatched direction of expression across studies by incorporating the 
direction of expression information. More importantly, in the subset of DEGs which were 
present in all three datasets, 5.26% of DEGs had conflicting direction of expression across 
studies. Although, small in proportion, this would be of importance in case a gene of interest 
for the disease being studied has conflicting direction of expression across different studies. 
Particularly when more datasets are included in meta-analysis, the number of genes considered 
in IN approach can be massively reduced. 
 
Given that the FIN method has the highest power of DEG detection, we further explore the 
DEGs obtained using this meta-analysis procedure. Top 10 up and down-regulated DEGs 
identified by FIN method are presented in Table 3. For full list of DEGs identified by different 
meta-analysis methods, see Supplementary 2, 3 and 4. In terms of effective direction of 
expression of DEGs, 2914 DEGs with same direction of expression across studies and 180 
DEGs with mismatched direction of expression were up-regulated. Similarly, 2989 (same 
direction) and 55 (mismatched direction) DEGs were down-regulated. Results for scenario 2 
for random selection have been detailed in Supplementary 1: Table 3, 4 and 5. 
 
Table 3. Top 10 up- and down-regulated DEGs identified by FIN method. The DEGs have 
been sorted based on the value of the statistic 𝑁𝑔 and the mean of absolute value of the log2 𝐹𝐶 
have been reported. Effect signifies the direction of expression of DEGs in the per-study 













EIF4EBP1 10.45 3.33 +++ < 1.62 × 10−15 SMAD12 11.19 4.32 --- < 1.62 × 10−15 
WEE1 10.39 4.04 +++ < 1.62 × 10−15 RASGRF2 11.10 4.19 --- < 1.62 × 10−15 
VIM 10.39 3.68 +++ < 1.62 × 10−15 DNAJC6 11.07 3.71 --- < 1.62 × 10−15 
NUSAP1 10.29 4.67 +++ < 1.62 × 10−15 SERPINI1 10.99 4.79 --- < 1.62 × 10−15 
HJURP 10.24 5.79 +++ < 1.62 × 10−15 ATP1B1 10.98 3.35 --- < 1.62 × 10−15 
KIF4A 10.15 4.48 +++ < 1.62 × 10−15 ATP8A1 10.91 3.95 --- < 1.62 × 10−15 
KIF20A 10.12 5.80 +++ < 1.62 × 10−15 JAKMIP3 10.91 4.40 --- < 1.62 × 10−15 
AURKB 10.09 5.48 +++ < 1.62 × 10−15 MFSD6 10.90 2.83 --- < 1.62 × 10−15 
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UBE2C 10.07 5.95 +++ < 1.62 × 10−15 DCTN1-AS1 10.88 5.33 --- < 1.62 × 10−15 
CCNB2 10.04 4.63 +++ < 1.62 × 10−15 PRKACB 10.85 2.35 --- < 1.62 × 10−15 
 
Pathway analysis and biological significance 
DEGs obtained by the FIN method were further explored to assess their biological relevance 
to GBM. QIAGEN’s Ingenuity Pathway Analysis (IPA) (www.qiagen.com/ingenuity) tool was 
used to identify biological pathways in which DEGs were enriched and upstream regulator 
analysis (URA) identified upstream regulators for GBM. We performed pathway analysis and 
URA separately for DEGs that were up-regulated and down-regulated and were present in all 
three datasets. We also note that not all identified DEGs by the meta-analysis methods are 
present in all three studies considered. Number of DEGs present in one, two or all three datasets 
have been detailed in Table 4.  
 
Table 4. Number of DEGs found in one, two or all three datasets. Same and mismatched 








































Of 1798 up-regulated DEGs, all of them mapped in the IPA database and 128 canonical 
pathways were identified based on BH adjusted p-value (< 0.01).  These include Heptatic 
Fibrosis Signaling Pathway (adj. Pval. = 3.98 × 10−13, ratio = 0.205), Kinetochore Metaphase 
Signaling Pathway (adj. Pval. = 7.94 × 10−15, ratio = 0.376), Cell Cycle Control of 
Chromosomal Replication (adj. Pval. = 5.89 × 10−09, ratio = 0.393), Role of BRCA1 in DNA 
Damage Response (adj. Pval. = 1.32 × 10−08, ratio = 0.325) and IL-8 Signaling (adj. Pval. =
4.37 × 10−08, ratio = 0.215) as some of the top dysregulated pathways. More importantly, 
major aberrant pathways shown to be involved in GBM pathogenesis [32][33] were also 
identified and include Glioblastoma Multiforme Signaling (adj. Pval. = 2.95 × 10−06, ratio = 
0.206), Glioma Signaling (adj. Pval. = 3.63 × 10−05, ratio = 0.205), p53 Signaling (adj. Pval. 
= 5.25 × 10−05, ratio = 0.224), Glioma Invasiveness Signaling (adj. Pval. = 0.0008, ratio = 
0.219), PI3K/AKT Signaling (adj. Pval. = 0.005, ratio = 0.146) and mTOR Signaling (adj. 
Pval. = 0.007, ratio = 0.138).  
 
Similarly, all 1845 down-regulated DEGs mapped to the IPA database and 98 canonical 
pathways were identified as significant (BH adjusted p-value < 0.01). Synaptogenesis 
Signaling Pathway (adj. Pval. = 3.16 × 10−25, ratio = 0.288), Endocannabinoid Neuronal 
Synapse Pathway (adj. Pval. = 1.00 × 10−16, ratio = 0.359), Opioid Signaling Pathway (adj. 
Pval. = 1.00 × 10−13, ratio = 0.247), GNRH Signaling (adj. Pval. = 6.31 × 10−11, ratio = 
0.260), Calcium Signaling (adj. Pval. = 6.31 × 10−11, ratio = 0.243), G Beta Gamma 
Signaling (adj. Pval. = 9.33 × 10−10, ratio = 0.287) and Dopamine-DARPP32 Feedback in 
cAMP Signaling (adj. Pval. = 1.55 × 10−09, ratio = 0.252) were identified as some of the top 
dysregulated pathways. The top 10 pathways identified by the up-regulated and down-
regulated DEGs separately are illustrated in Figure 5. For complete list of identified pathways 
for up- and down-regulated DEGs in our study, see Supplementary 1: Table 6. 
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Figure 5. Significant pathways identified by IPA. The top ten significant pathways based on 
BH p-value among the canonical pathways identified by IPA for the up-regulated DEGs 
(orange bar) and down-regulated DEGs (green bar). The numbers on the bar plot show the ratio 
between the numbers of DEGs enriched and total number of genes in each of these pathways. 
 
In addition, the URA tool in IPA identified potential upstream regulators (transcription factors, 
genes or other small molecules) that has been experimentally observed to affect gene 
expression. It identifies these regulators by analysing linkage to DEGs through coordinated 
expression [34]. Among the up-regulated DEGs, TGFB1 and TP53, which are also DEGs and 
important in GBM pathogenesis [35][36] are predicted to be the top two upstream regulators. 
293 up-regulated DEGs were identified as potential upstream regulators of gene upregulation 
out of a total of 2215 (BH corrected p-value < 0.01, see Supplementary 1: Table 7a) predicted 
upstream regulators. Out of 2215 predicted, 764 of these significant upstream regulators were 
activated and 112 were also observed as DEGs in our analysis.  
 
On the contrary, for the down-regulated DEGs, IPA identified 32 potential upstream regulators 
(BH corrected p-value < 0.01, see Supplementary 1: Table 7b) with TCF7L2 and MAPT as the 
top two. 14 of the 32 upstream regulated were predicted to be inhibited and two among the 
inhibited are DEGs. TCF7L2 is a diabetes risk-associated gene which plays a key role in the 
Wnt-signaling pathway and is shown to be frequently mutated in colorectal cancer [37] and 
promote cell proliferation [38]. However, exploration of its role in GBM pathogenesis warrant 
further studies. Interestingly, MAPT is also a DEG observed in our analysis and is one of the 
two hallmarks of AD [39]. Gargini et al. (2019) [40] observed a strong correlation of 
Tau/MAPT expression and indicators of survival in glioma patients. Moreover, it has been 
found to be epigenetically controlled by balance between IDH1/2 wild-type and mutation in 
human gliomas [41]. Thus, providing further evidence and reaffirming the involvement of 
MAPT in central nervous system disorders. 
 
Of the DEGs with conflicting direction of expression across studies, 182 out of 235 DEGs are 
present in all three datasets. Among them CMTM6, RAD51, NOS1AP, MSANTD1, PGM2, 
PSD3, GPR82, SPTBN4, TSPAN6 and ARHGEF28 were identified as top 10 DEGs based on 
the absolute value of 𝑁𝑔 (see Table 5). Interestingly, RAD51 and ARHGEF28 have previously 
been identified as a tumour suppressor and an oncogene respectively [42]. More importantly, 
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RAD51 was found to be effectively overexpressed in GBM in our study and have recently been 
shown as a target for inhibition to enhance radiosensitivity of GBM cells during treatment 
[43][44]. On the other hand, ARHGEF28 was found to be effectively down-regulated in our 
study. It is an intracellular kinase that functions either as a Rho guanine exchange factor or a 
scaffolding protein to initiate FAK activation and cell contractibility [45]. Furthermore, the 
RhoA-FAK pathway has been shown to be involved in colon cancer cell proliferation and 
migration [46]. ARHGEF28 mRNA levels have also been found to be elevated in late-stage 
ovarian cancer and associated with decreased progression free and overall survival [47]. 
However, its role in GBM growth and progression is yet to be elucidated and requires 
exploration in future studies.  
 
Table 5. Top 10 DEGs with mismatched direction of expression across datasets identified by 
FIN method. The DEGs have been sorted based on the absolute value of the statistic 𝑁𝑔 and 
the mean of absolute value of the log2 𝐹𝐶 have been reported. Effect signifies the direction of 
expression of DEGs in the per-study differential analysis for GSE123892, GSE151352 and 
TCGA-GBM respectively.  
DEGs 𝑵𝒈 Mean |logFC| Effect BH p-value 
CMTM6 7.58 1.30 +-+ 3.93 × 10−13 
RAD51 7.58 2.82 +-+ 4.03 × 10−13 
NOS1AP -7.53 1.37 -+- 5.73 × 10−13 
MSANTD1 -7.53 1.31 -+- 5.92 × 10−13 
PGM2 7.52 1.31 +-+ 6.35 × 10−13 
PSD3 -7.47 1.67 -+- 8.63 × 10−13 
GPR82 7.43 4.35 +-+ 1.24 × 10−12 
SPTBN4 -7.31 1.91 -+- 2.78 × 10−12 
TSPAN6 7.18 2.08 +-+ 6.86 × 10−12 
ARHGEF28 -7.06 1.23 +-- 1.63 × 10−11 
 
Additional considerations 
Although the implementation of MIN and FIN p-value combination methods are straight 
forward, they require some additional considerations. First, the used weighting criteria leads to 
a larger weight being given to a study with larger sample sizes. Intuitively, this is expected as 
a study with a larger sample size might be more robust than studies with lower sample sizes. 
However, importance must also be given to the quality of the RNA-seq data in each study. It 
must be assessed in case this information is available and other weights more appropriate as 
per the quality of the data may be specified. In our study, since TCGA-GBM has a much larger 
sample size as compared to the other two datasets, we compared the number of DEGs obtained 
by FIN method by considering all 165 samples and 10 random selections of 20 cases and 5 
normal samples. On average, about 94% of the DEGs obtained when randomly selected subset 
was considered were also found in DEGs identified using the full TCGA-GBM dataset (see 
Supplementary 1: Table 8). Hence, suggesting that the identification of DEGs was stable across 
these two settings.  
 
Next, the MIN and FIN are adaptive in a sense that they allow for consideration of genes that 
may not be present in all studies that are considered for integrated differential expression 
analysis. In case a gene is not present in some of the studies, the weights (𝑤𝑠) in the 
combination method can only be estimated using the number of replicates in the datasets in 
which the gene is present. However, for genes that are just present in one study, it would mean 
that the results from the meta-analysis for these genes would be the same as the per-study 
differential analysis. Hence, a careful consideration about the quality of the RNA-seq data and 
library size is required in case only the genes that are common among studies are considered. 
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For datasets of similar quality and library size, a large proportion of genes would not be 
excluded from meta-analysis if only common genes are used. However, a large number of 
genes might be excluded from meta-analysis in case of dissimilar library sizes and quality 
which could lead to potentially missing out on important genes for the disease. For instance, 
only 12345 out of 18315 unique genes are present in all 3 studies in our application where the 
library sizes are not similar. Thus, a balanced approach is suggested. 
 
Finally, we used edgeR for per-study differential analysis in our study but other popular 
packages such as DESeq2 [48] and NOIseq [31] can be applied. Moreover, the FIN model can 
be extended to multi-group comparisons apart from a two-group comparison discussed in this 
study. The proposed meta-analysis method relies on the fact that the same test statistics are 
used for per-study differential expression analysis to obtain individual p-values and all studies 
under consideration have the same experimental considerations. For instance, in case DESeq2 
is used for multi-group differential expression analysis in each study, a likelihood ratio test is 
used rather than Wald statistics being used for two group differential expression analysis. 
 
Conclusions 
In this study, we proposed MIN and consequently FIN method for meta-analysis of RNA-seq 
data. The developed methods account for both the sample size of study and direction of 
expression of a gene in each study allowing for detection of potentially robust biologically 
significant DEGs even when they have conflicting direction of expression across studies. In 
contrast with the existing IN method, proposed methods have the advantage of identifying 
DEGs among genes with conflicting direction of expression across studies. For the genes with 
concordant differential expression patterns across studies the MIN method exhibited a similar 
DEG detection power and performance as compared to IN method particularly when there was 
high inter-study variability and increased number of studies were considered. FIN method 
exhibited a similar or improved DEG detection power as compared to IN method and was 
significantly better in performance as compared to MIN method. More importantly, in a real 
data application, we demonstrated the use of FIN method in detection of biologically relevant 
DEGs to GBM. Hence, this meta-analysis method provides a way to establish differential 
expression status for genes with conflicting direction of expression in individual RNA-seq 
studies and further exploration of them as potential biomarkers for the disease. With lowering 
costs and increase in the number of RNA-seq studies being archived on public databases, this 
method might provide a way to integrate a greater number of studies without losing much prior 
information and consequently considering all the genes in the analysis irrespective of their 
direction of expression. 
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obtained when randomly selected subset was considered were also found in DEGs 
identified using the full TCGA-GBM dataset. 
 
13. Supplementary 2. Full list of DEGs identified in scenario 1 by the inverse-normal 
method in GBM data application (in an Excel file). 
 
14. Supplementary 3. Full list of DEGs identified in scenario 1 by the modified inverse-
normal method in GBM data application (in an Excel file). 
 
15. Supplementary 4. Full list of DEGs identified in scenario 1 by the fused inverse-
normal method in GBM data application (in an Excel file). 
 
Interpretations of the FIN model 
 
In order to understand the practical behaviour and interpretations of the FIN model in different 
scenarios, we consider the following cases in terms of differential expression of a gene and its 
direction of expression (up: +, down: -) in individual studies: 
 
i. A gene is non differentially expressed (NDE) in one study and differentially 
expressed (DE) in another: If it is NDE, Φ−1(1 − 𝑝𝑔𝑠)  is standard normal 
distributed. Hence, it takes values around 0 with high probability. On the 
contrary, if it is DE, Φ−1(1 − 𝑝𝑔𝑠)  will take extreme values. Now, the value of 
𝑁𝑔  will then depend on which study has the larger weight (𝑤𝑠). 
ii. A gene is strongly +DE in one study and strongly -DE in another: In this case, 
Φ−1(1 − 𝑝𝑔𝑠) will be extreme for both studies. Then, if the weight 𝑤𝑠 is similar 
for both studies, the contribution of the study specific term to 𝑁𝑔 will cancel 
each other out because of 𝐵𝑔𝑠. Hence, 𝑁𝑔  which will be close to 0 will give us 
non-significant p-value in hypothesis testing for that gene. This makes sense as 
we will have comparable evidence of conflicting direction of expression for the 
gene. In case, the weight of one study is comparatively larger than the other 
study, we will get that the gene is DE with the effective sign of regulation of 
that of the bigger study. 
iii. A gene is strongly +DE in most studies and weakly -DE in a few: Similar to 
case ii, Φ−1(1 − 𝑝𝑔𝑠) will be extreme for all the studies. For comparable 
weights of studies, we would get a large positive value for 𝑁𝑔 as we have many 
more studies where the gene is +DE as compared to where the gene is -DE. 
Hence, resulting in the gene to be +DE after hypothesis testing. Only in case 
when the study where the gene is -DE has an extremely larger weight 𝑤𝑠 as 
compared to all other four studies combined can that gene be -DE as a result of 
the hypothesis testing.  
 
Simulation study model 
 
Here, we briefly describe the theoretical framework of the simulation study method adapted 
from Rau et al. (2014) [reference 10 in the manuscript]. For detailed procedure for estimation 
of parameter values based on real RNA-seq datasets (GSE125583 in this study), see Rau et al. 
(2014). 
 
Let 𝑌𝑔𝑐𝑟𝑠 be random variable with 𝑦𝑔𝑐𝑟𝑠 as its realisations which are observed count for a gene 
𝑔, condition 𝑐, biological replicate 𝑟 and study 𝑠. RNA-seq data was generated as per the 
negative binomial distribution, 
𝑌𝑔𝑐𝑟𝑠 ∼ 𝑁𝐵(𝜇𝑔𝑐𝑠 , 𝜙𝑔𝑠) 
 
where parameters 𝜇𝑔𝑐𝑠 and 𝜙𝑔𝑠 represent the mean and dispersion, respectively, for a gene 𝑔, 
condition 𝑐 and study 𝑠. To account for variability between the individual studies (inter-study 
variability) considered for meta-analysis, we consider the following situation: 
 
𝜇𝑔𝑐𝑠 = 𝜃𝑔𝑐 × 𝑒
𝜖𝑔𝑐𝑠 
where 𝜖𝑔𝑐𝑠 ∼ 𝑁(0, 𝜎
2). 𝜃𝑔𝑐  is the mean for a gene 𝑔 in condition 𝑐. 𝜖𝑔𝑐𝑠  represents the 
variability around 𝜃𝑔𝑐  due to a study and condition specific random effect. 𝜎
2 represents the 
size of the inter-study variability which affects 𝜇𝑔𝑐𝑠 through 𝜖𝑔𝑐𝑠 with 𝜖𝑔𝑐𝑠 having a 
multiplicative effect on 𝜇𝑔𝑐𝑠 .  
 
Processing of raw RNA-seq dataset GSE151352 using GALAXY 
 
Raw fastq files generated by GPL23934 (Ion Torrent S5 (Homo sapiens)) platform were 
retrieved for all 24 samples (12 tumour and 12 healthy) from Sequence Read Archive 
(https://trace.ncbi.nlm.nih.gov/Traces/sra/sra.cgi?study=SRP265074) using Get Data tool in 
Galaxy. Next, we assessed the quality of the raw reads using quality reports from FastQC and 
removed the specified adapter sequence ATCACCGACTGCCCATAGAGAGGCTGAGAC 
with Cutadapt (version 1.16). The parameters used for this step were the parameters provided 
by the submitted of the dataset on Gene Expression Omnibus. The adapter trimmed reads were 
again assessed for quality by FastQC and were aligned to the reference genome (GRCh37.p13, 
genecode v19) using a 2-pass method with RNA STAR (Galaxy version 2.7.5b) where other 
parameters used were default parameters. Following alignment, the generated BAM files were 
processed using the featureCounts tool (Galaxy version 1.6.4+galaxy2) to get raw counts for 
each RNA-seq data sample. 
 
 
Figure 1.  Flow of different steps used in processing of the raw RNA-seq fastq files for 
GSE151352 using Galaxy to get raw counts. 
 
Supplementary Table 1. Total number of genes (# genes), number of genes with conflicting 
direction of expression (# conf. genes), number of differentially expressed genes (# DEGs), 
number of genes with conflicting direction of expression (# conf. DEGs) and number of true 






# conf. genes 
(IN/MIN/FIN) 
# DEGs  
(IN, MIN, FIN) 
# conf. DEGs 
(IN, MIN, FIN) 
# true 
DEGs 
0.15, 3 16776  19 10099  49 2268  38, 2611  49, 2441  45 0, 243  18, 236  18 6436  10 
0.15, 5 16871  17 13036  43 2431  35, 4031  47, 3741  45 0, 1365  39, 1337  38 6468  9 
0.5, 3 17002  45 11490  57 2098  35, 3879  46, 3741  44 0, 1706  35, 1697  35 6501  19 
0.5, 5 17266  34 14824  48 1124  31, 4453  48, 4365  46 0, 3264  46, 3257  45 6585  15 
 
 
Supplementary Table 2. Total number of up and down-regulated DEGs identified in per-
study differential analysis in 10 random selections of 20 GBM cases and 5 controls from 
TCGA-GBM dataset. 
 
TCGA-GBM DEGs (Up) DEGs (Down) Total 
Selection 1 3112 3016 6128 
Selection 2 3323 3013 6336 
Selection 3 3204 3030 6234 
Selection 4 3285 3054 6339 
Selection 5 3267 3077 6344 
Selection 6 3249 3069 6318 
Selection 7 3293 2968 6261 
Selection 8 3792 2885 6677 
Selection 9 3311 3025 6336 
Selection 10 3229 3088 6317 
 
 
Supplementary Table 3. Number of DEGs identified by the inverse-normal (IN) method in 
the GBM data application for both scenarios and number of these DEGs present in one, two or 
all three datasets considered.  
 
Datasets DEGs 
Present in 1 
DEGs 
Present in 2 
DEGs  
Present in 3 
GSE123892, GSE151352, TCGA-GBM 
(all samples) 
1368 1085 3465 
GSE123892, GSE151352, TCGA-GBM 
(random selection 1) 
921 1082 3511 
GSE123892, GSE151352, TCGA-GBM 
(random selection 2) 
943 1080 3477 
GSE123892, GSE151352, TCGA-GBM 
(random selection 3) 
939 1079 3462 
GSE123892, GSE151352, TCGA-GBM 
(random selection 4) 
965 1080 3482 
GSE123892, GSE151352, TCGA-GBM 
(random selection 5) 
939 1076 3540 
GSE123892, GSE151352, TCGA-GBM 
(random selection 6) 
940 1100 3543 
GSE123892, GSE151352, TCGA-GBM 
(random selection 7) 
972 1055 3461 
GSE123892, GSE151352, TCGA-GBM 
(random selection 8) 
989 1106 3513 
GSE123892, GSE151352, TCGA-GBM 
(random selection 9) 
921 1083 3529 
GSE123892, GSE151352, TCGA-GBM 
(random selection 10) 
995 1080 3442 
 
 
Supplementary Table 4. Number of DEGs identified by the modified inverse-normal (MIN) 
method in the GBM data application for both scenarios and number of these DEGs present in 
one, two or all three datasets considered. a. For DEGs with the same direction of expression 
across all three studies. b. For DEGs with conflicting direction of expression across studies. 
 
a. For DEGs with the same direction of expression across all 3 studies 
Datasets DEGs 
Present in 1 
DEGs 
Present in 2 
DEGs  
Present in 3 
GSE123892, GSE151352, TCGA-GBM 
(all samples) 
1182 1087 3623 
GSE123892, GSE151352, TCGA-GBM 
(random selection 1) 
832 1081 3658 
GSE123892, GSE151352, TCGA-GBM 
(random selection 2) 
844 1099 3662 
GSE123892, GSE151352, TCGA-GBM 
(random selection 3) 
861 1089 3616 
GSE123892, GSE151352, TCGA-GBM 
(random selection 4) 
862 1088 3654 
GSE123892, GSE151352, TCGA-GBM 
(random selection 5) 
845 1078 3695 
GSE123892, GSE151352, TCGA-GBM 
(random selection 6) 
863 1107 3689 
GSE123892, GSE151352, TCGA-GBM 
(random selection 7) 
876 1062 3644 
GSE123892, GSE151352, TCGA-GBM 
(random selection 8) 
887 1094 3697 
GSE123892, GSE151352, TCGA-GBM 
(random selection 9) 
830 1097 3702 
GSE123892, GSE151352, TCGA-GBM 
(random selection 10) 
911 1090 3605 
 
 
b. For DEGs with the mismatched direction of expression across 3 studies 
Datasets DEGs 
Present in 1 
DEGs 
Present in 2 
DEGs  
Present in 3 
GSE123892, GSE151352, TCGA-GBM 
(all samples) 
0 52 181 
GSE123892, GSE151352, TCGA-GBM 
(random selection 1) 
0 26 140 
GSE123892, GSE151352, TCGA-GBM 
(random selection 2) 
0 41 171 
GSE123892, GSE151352, TCGA-GBM 
(random selection 3) 
0 38 149 
GSE123892, GSE151352, TCGA-GBM 
(random selection 4) 
0 34 166 
GSE123892, GSE151352, TCGA-GBM 
(random selection 5) 
0 28 154 
GSE123892, GSE151352, TCGA-GBM 
(random selection 6) 
0 33 140 
GSE123892, GSE151352, TCGA-GBM 
(random selection 7) 
0 39 173 
GSE123892, GSE151352, TCGA-GBM 
(random selection 8) 
0 30 179 
GSE123892, GSE151352, TCGA-GBM 
(random selection 9) 
0 39 165 
GSE123892, GSE151352, TCGA-GBM 
(random selection 10) 
0 34 164 
 
 
Supplementary Table 5. Number of DEGs identified by the fused inverse-normal (FIN) 
method in the GBM data application for both scenarios and number of these DEGs present in 
one, two or all three datasets considered. a. For DEGs with the same direction of expression 
across all three studies. b. For DEGs with conflicting direction of expression across studies 
 
a. For DEGs with the same direction of expression across all 3 studies 
Datasets DEGs 
Present in 1 
DEGs 
Present in 2 
DEGs  
Present in 3 
GSE123892, GSE151352, TCGA-GBM 
(all samples) 
1359 1083 3461 
GSE123892, GSE151352, TCGA-GBM 
(random selection 1) 
911 1080 3508 
GSE123892, GSE151352, TCGA-GBM 
(random selection 2) 
933 1077 3475 
GSE123892, GSE151352, TCGA-GBM 
(random selection 3) 
931 1070 3457 
GSE123892, GSE151352, TCGA-GBM 
(random selection 4) 
957 1077 3476 
GSE123892, GSE151352, TCGA-GBM 
(random selection 5) 
931 1073 3536 
GSE123892, GSE151352, TCGA-GBM 
(random selection 6) 
935 1096 3540 
GSE123892, GSE151352, TCGA-GBM 
(random selection 7) 
962 1051 3460 
GSE123892, GSE151352, TCGA-GBM 
(random selection 8) 
978 1101 3509 
GSE123892, GSE151352, TCGA-GBM 
(random selection 9) 
912 1078 3526 
GSE123892, GSE151352, TCGA-GBM 
(random selection 10) 
988 1076 3436 
 
b. For DEGs with the mismatched direction of expression across 3 studies 
Datasets DEGs 
Present in 1 
DEGs 
Present in 2 
DEGs  
Present in 3 
GSE123892, GSE151352, TCGA-GBM 
(all samples) 
0 53 182 
GSE123892, GSE151352, TCGA-GBM 
(random selection 1) 
0 26 140 
GSE123892, GSE151352, TCGA-GBM 
(random selection 2) 
0 41 171 
GSE123892, GSE151352, TCGA-GBM 
(random selection 3) 
0 38 149 
GSE123892, GSE151352, TCGA-GBM 
(random selection 4) 
0 34 166 
GSE123892, GSE151352, TCGA-GBM 
(random selection 5) 
0 28 154 
GSE123892, GSE151352, TCGA-GBM 
(random selection 6) 
0 32 140 
GSE123892, GSE151352, TCGA-GBM 
(random selection 7) 
0 39 172 
GSE123892, GSE151352, TCGA-GBM 
(random selection 8) 
0 30 179 
GSE123892, GSE151352, TCGA-GBM 
(random selection 9) 
0 39 165 
GSE123892, GSE151352, TCGA-GBM 
(random selection 10) 
0 34 164 
 
 
Supplementary Table 6. IPA canonical pathways for a. up and b. down-regulated DEGs 
present in all three GBM datasets and identified by the FIN method. Ratio denotes the number 
of DEGs enriched in a pathway to the total number of genes in that pathway. 
 
Ingenuity Canonical Pathways -log(BH p-value) Ratio z-score 
a. Pathways from up-regulated DEGs 
Kinetochore Metaphase Signaling Pathway 14.1 0.376 3.413 
Hepatic Fibrosis Signaling Pathway 12.4 0.205 7.714 
Osteoarthritis Pathway 11.1 0.241 5.126 
Cell Cycle Control of Chromosomal Replication 8.23 0.393 4.69 
Role of BRCA1 in DNA Damage Response 7.88 0.325 2.837 
IL-8 Signaling 7.36 0.215 5.84 
Tumor Microenvironment Pathway 6.56 0.216 4.867 
Estrogen-mediated S-phase Entry 6.32 0.5 2.496 
Death Receptor Signaling 6.19 0.272 3.4 
GP6 Signaling Pathway 6.17 0.244 5.385 
Acute Phase Response Signaling 5.98 0.206 4.596 
Colorectal Cancer Metastasis Signaling 5.9 0.182 5.376 
Dendritic Cell Maturation 5.76 0.201 5.831 
Glioblastoma Multiforme Signaling 5.53 0.206 4.158 
ILK Signaling 5.43 0.195 4.7 
FAT10 Cancer Signaling Pathway 5.43 0.348 2 
EIF2 Signaling 5.35 0.183 2.711 
Senescence Pathway 5.32 0.171 1.021 
Type I Diabetes Mellitus Signaling 5.27 0.234 3.441 
Regulation Of The Epithelial Mesenchymal Transition By Growth 
Factors Pathway 
5.16 0.191 5.667 
Production of Nitric Oxide and Reactive Oxygen Species in 
Macrophages 
5.12 0.19 5.24 
Neuroinflammation Signaling Pathway 5.03 0.163 6.112 
HOTAIR Regulatory Pathway 5.01 0.2 3.772 
Cyclins and Cell Cycle Regulation 5 0.259 1.528 
Signaling by Rho Family GTPases 4.87 0.17 5.745 
Role of PKR in Interferon Induction and Antiviral Response 4.84 0.22 3.411 
Leukocyte Extravasation Signaling 4.58 0.181 3.889 
Pancreatic Adenocarcinoma Signaling 4.5 0.22 2.84 
Glioma Signaling 4.44 0.218 3.317 
HIF1 Signaling 4.43 0.176 4.333 
Tec Kinase Signaling 4.39 0.185 4.796 
p53 Signaling 4.28 0.224 0.535 
Inhibition of Angiogenesis by TSP1 4.26 0.353 2.53 
Regulation of Cellular Mechanics by Calpain Protease 3.95 0.243 1.732 
IL-6 Signaling 3.94 0.198 4.491 
STAT3 Pathway 3.87 0.193 2.982 
Bladder Cancer Signaling 3.86 0.216 2 
TNFR1 Signaling 3.76 0.28 3.051 
Ovarian Cancer Signaling 3.67 0.187 3.317 
Apoptosis Signaling 3.67 0.21 1.789 
BEX2 Signaling Pathway 3.6 0.228 2.828 
Breast Cancer Regulation by Stathmin1 3.57 0.125 6.215 
Mitotic Roles of Polo-Like Kinase 3.54 0.242 1.069 
MSP-RON Signaling In Cancer Cells Pathway 3.54 0.187 4.6 
Aryl Hydrocarbon Receptor Signaling 3.51 0.182 0.894 
Systemic Lupus Erythematosus In B Cell Signaling Pathway 3.47 0.149 4.841 
ATM Signaling 3.43 0.206 0.775 
TREM1 Signaling 3.42 0.227 4.123 
Induction of Apoptosis by HIV1 3.42 0.246 2.84 
NF-B Signaling 3.42 0.168 4.747 
Notch Signaling 3.25 0.297 1.414 
Myc Mediated Apoptosis Signaling 3.23 0.26 2.496 
Sphingosine-1-phosphate Signaling 3.21 0.188 1.706 
Fc Receptor-mediated Phagocytosis in Macrophages and 
Monocytes 
3.18 0.202 4.359 
Glioma Invasiveness Signaling 3.09 0.219 2.5 
Th2 Pathway 3.09 0.176 1.732 
Crosstalk between Dendritic Cells and Natural Killer Cells 3.04 0.202 3.464 
Cytotoxic T Lymphocyte-mediated Apoptosis of Target Cells 2.94 0.294 2.449 
Regulation Of The Epithelial Mesenchymal Transition In 
Development Pathway 
2.87 0.202 3.742 
TWEAK Signaling 2.84 0.286 1.897 
Integrin Signaling 2.84 0.15 4.914 
Tumoricidal Function of Hepatic Natural Killer Cells 2.73 0.333 2.646 
Ephrin Receptor Signaling 2.72 0.153 3.5 
NER Pathway 2.71 0.184 2.828 
Role of Pattern Recognition Receptors in Recognition of Bacteria 
and Viruses 
2.71 0.162 3.742 
Wnt/-catenin Signaling 2.67 0.156 1.4 
Complement System 2.67 0.27 1.414 
Protein Kinase A Signaling 2.52 0.125 0.686 
fMLP Signaling in Neutrophils 2.5 0.172 3.207 
LPS/IL-1 Mediated Inhibition of RXR Function 2.47 0.142 0.943 
Actin Cytoskeleton Signaling 2.41 0.141 4.2 
GM-CSF Signaling 2.36 0.2 2.496 
VDR/RXR Activation 2.36 0.192 0.707 
HGF Signaling 2.34 0.167 3.357 
HMGB1 Signaling 2.32 0.152 4.583 
Small Cell Lung Cancer Signaling 2.32 0.197 2.333 
Th1 Pathway 2.31 0.165 2.84 
Semaphorin Neuronal Repulsive Signaling Pathway 2.29 0.158 0.853 
PI3K/AKT Signaling 2.28 0.146 2.673 
Acute Myeloid Leukemia Signaling 2.23 0.18 2.53 
TNFR2 Signaling 2.13 0.267 1.89 
Role of NFAT in Regulation of the Immune Response 2.12 0.144 4.472 
mTOR Signaling 2.1 0.138 3.464 
Glutathione Redox Reactions I 2.1 0.292 2.646 
Androgen Signaling 2.09 0.154 1.667 
Cardiac Hypertrophy Signaling (Enhanced) 2.09 0.115 6.934 
Toll-like Receptor Signaling 2.07 0.184 2.496 
iNOS Signaling 2.07 0.222 2.828 
Mouse Embryonic Stem Cell Pluripotency 2 0.165 3.638 
 
Ingenuity Canonical Pathways -log(BH p-value) Ratio z-score 
b. Pathways from down-regulated DEGs 
Synaptogenesis Signaling Pathway 24.5 0.288 -8.013 
Endocannabinoid Neuronal Synapse Pathway 16 0.359 -4.727 
Role of NFAT in Cardiac Hypertrophy 14.1 0.271 -6.456 
Opioid Signaling Pathway 13 0.247 -6.04 
GNRH Signaling 10.2 0.26 -5.477 
Calcium Signaling 10.2 0.243 -6.091 
G Beta Gamma Signaling 9.03 0.287 -5.396 
Dopamine-DARPP32 Feedback in cAMP Signaling 8.81 0.252 -4.902 
Synaptic Long Term Depression 8.38 0.233 -5.555 
GPCR-Mediated Nutrient Sensing in Enteroendocrine Cells 8.26 0.286 -5.303 
Neuropathic Pain Signaling In Dorsal Horn Neurons 8.22 0.297 -5.477 
Reelin Signaling in Neurons 7.97 0.27 -5.657 
Netrin Signaling 7.85 0.354 -4.796 
Synaptic Long Term Potentiation 7.38 0.256 -5.209 
CCR5 Signaling in Macrophages 7.09 0.287 -3.464 
Melatonin Signaling 6.93 0.319 -3.545 
CXCR4 Signaling 6.58 0.222 -4.041 
Protein Kinase A Signaling 6.55 0.165 -2.84 
Signaling by Rho Family GTPases 6.44 0.19 -5.24 
Corticotropin Releasing Hormone Signaling 6.17 0.228 -1.095 
Cardiac Hypertrophy Signaling 5.91 0.188 -5.754 
Apelin Endothelial Signaling Pathway 5.85 0.243 -3.657 
Sperm Motility 5.57 0.188 -5.099 
Thrombin Signaling 5.54 0.192 -4.271 
Nitric Oxide Signaling in the Cardiovascular System 5.54 0.253 -4.491 
Cardiac -adrenergic Signaling 5.53 0.22 -2.837 
Androgen Signaling 5.38 0.221 -4.583 
-Adrenergic Signaling 5.25 0.25 -3.873 
Superpathway of Inositol Phosphate Compounds 5.24 0.191 -6.083 
Type II Diabetes Mellitus Signaling 4.99 0.211 -3.051 
Gq Signaling 4.94 0.203 -5.196 
Glutamate Receptor Signaling 4.75 0.298 -1.89 
cAMP-mediated signaling 4.6 0.175 -5.096 
Huntington's Disease Signaling 4.58 0.173 -1.706 
nNOS Signaling in Neurons 4.57 0.319 -3 
3-phosphoinositide Biosynthesis 4.5 0.193 -5.568 
White Adipose Tissue Browning Pathway 4.44 0.209 -4.426 
CREB Signaling in Neurons 4.42 0.134 -7.778 
Insulin Secretion Signaling Pathway 4.3 0.168 -5.778 
FcRIIB Signaling in B Lymphocytes 4.27 0.253 -2.449 
Renin-Angiotensin Signaling 4.22 0.212 -4.583 
Adrenomedullin signaling pathway 4.18 0.178 -5.657 
D-myo-inositol-5-phosphate Metabolism 4.18 0.191 -5.385 
14-3-3-mediated Signaling 4.15 0.205 -3.838 
Endothelin-1 Signaling 3.84 0.176 -4.131 
Phospholipase C Signaling 3.8 0.158 -4.914 
Relaxin Signaling 3.74 0.187 -3.606 
D-myo-inositol (1,4,5,6)-Tetrakisphosphate Biosynthesis 3.74 0.19 -5.099 
D-myo-inositol (3,4,5,6)-tetrakisphosphate Biosynthesis 3.74 0.19 -5.099 
Cholecystokinin/Gastrin-mediated Signaling 3.74 0.202 -4.583 
P2Y Purigenic Receptor Signaling Pathway 3.72 0.197 -4.264 
Apelin Cardiomyocyte Signaling Pathway 3.58 0.212 -4.583 
CDK5 Signaling 3.49 0.204 -2.4 
CCR3 Signaling in Eosinophils 3.46 0.194 -3.742 
3-phosphoinositide Degradation 3.46 0.179 -5.196 
Chemokine Signaling 3.41 0.225 -3.638 
Aldosterone Signaling in Epithelial Cells 3.38 0.177 -4.359 
Cardiac Hypertrophy Signaling (Enhanced) 3.13 0.129 -7.366 
PKC Signaling in T Lymphocytes 3.13 0.174 -3.742 
Endocannabinoid Developing Neuron Pathway 3.11 0.191 -1.606 
Sphingosine-1-phosphate Signaling 3.01 0.188 -2.828 
ErbB Signaling 2.99 0.202 -4.243 
UVB-Induced MAPK Signaling 2.9 0.25 -3.606 
p70S6K Signaling 2.82 0.178 -3.13 
Rac Signaling 2.82 0.182 -4.243 
Tec Kinase Signaling 2.75 0.162 -4.123 
RhoA Signaling 2.73 0.179 -3.13 
Pregnenolone Biosynthesis 2.73 0.462 -2.449 
Gs Signaling 2.73 0.187 -3.3 
IL-1 Signaling 2.69 0.196 -1.89 
fMLP Signaling in Neutrophils 2.69 0.181 -4.243 
Ephrin B Signaling 2.52 0.208 -3.317 
HGF Signaling 2.51 0.175 -4.243 
RhoGDI Signaling 2.51 0.153 2.828 
Ephrin Receptor Signaling 2.51 0.153 -4.583 
GPCR-Mediated Integration of Enteroendocrine Signaling 
Exemplified by an L Cell 
2.47 0.205 -0.258 
IL-8 Signaling 2.44 0.15 -4.796 
Leptin Signaling in Obesity 2.41 0.203 -2.236 
Histidine Degradation VI 2.4 0.4 -2.449 
B Cell Receptor Signaling 2.31 0.151 -4.041 
Role of NFAT in Regulation of the Immune Response 2.17 0.149 -3.838 
PI3K Signaling in B Lymphocytes 2.11 0.159 -4.472 
Ubiquinol-10 Biosynthesis (Eukaryotic) 2.09 0.353 -2.449 
ERK/MAPK Signaling 2.09 0.144 -3 
Amyotrophic Lateral Sclerosis Signaling 2.05 0.175 -2.111 
RANK Signaling in Osteoclasts 2.04 0.18 -4 
Neuroinflammation Signaling Pathway 2.03 0.13 -2.785 
UVA-Induced MAPK Signaling 2.01 0.173 -3.464 
 
 
Supplementary Table 7. IPA upstream regulator analysis results for a. up and b. down-
regulated DEGs present in all three GBM datasets and identified by the FIN method.  
 
Upstream Regulator mean|logFC| Molecule Type Activation z-score P-value overlap BH p-value 
a. Upstream regulators for up-regulated DEGs 
TGFB1 1.041 growth factor 8.971 2.51E-88 2.08E-84 
TP53 2.208 transcription 
regulator 
3.96 9.95E-80 4.14E-76 
ERBB2 1.26 kinase 7.269 2.60E-66 3.60E-63 
MYC 2.687 transcription 
regulator 
4.855 4.37E-62 4.55E-59 
CDKN1A 2.457 kinase -4.091 2.34E-56 1.77E-53 
NFKBIA 1.272 transcription 
regulator 
3.344 1.80E-43 7.47E-41 
FOXM1 4.83 transcription 
regulator 
7.238 5.80E-39 1.79E-36 
EGFR 4.605 kinase 5.001 9.51E-37 2.64E-34 
CCND1 1.251 transcription 
regulator 
4.578 2.88E-33 5.44E-31 
YAP1 1.162 transcription 
regulator 
5.297 7.46E-32 1.29E-29 
TWIST1 1.889 transcription 
regulator 
4.192 7.09E-30 1.02E-27 
E2F1 1.146 transcription 
regulator 
5.853 1.04E-28 1.35E-26 
TBX2 3.103 transcription 
regulator 
4.433 7.35E-28 8.86E-26 
NUPR1 1.918 transcription 
regulator 
-3.927 1.43E-26 1.51E-24 
AR 2.049 ligand-dependent 
nuclear receptor 
3.669 1.19E-25 1.15E-23 
JUN 1.495 transcription 
regulator 
5.72 2.87E-25 2.57E-23 
NR1H3 1.074 ligand-dependent 
nuclear receptor 
2.203 1.23E-24 1.05E-22 
AKT1 1.066 kinase 4.256 3.66E-24 2.92E-22 
VEGFA 3.776 growth factor 6.513 1.21E-23 9.28E-22 
SPI1 1.254 transcription 
regulator 
1.876 1.63E-23 1.22E-21 
TCF3 1.887 transcription 
regulator 
-0.806 9.61E-23 6.50E-21 
FAS 1.754 transmembrane 
receptor 
-2.084 2.13E-22 1.42E-20 
TGFB2 1.198 growth factor 3.424 5.11E-22 3.32E-20 
CD44 2.568 other 4.541 2.28E-20 1.27E-18 
APOE 1.358 transporter -4.791 2.73E-19 1.39E-17 
IRF1 2.009 transcription 
regulator 
5.486 9.97E-19 4.74E-17 
CEBPB 1.262 transcription 
regulator 
5.281 1.01E-18 4.77E-17 
FN1 2.971 enzyme 5.104 2.56E-17 1.10E-15 
CDK4 3.341 kinase 0.469 6.10E-17 2.51E-15 
ANGPT2 3.221 growth factor 6.136 6.54E-17 2.68E-15 
CCN2 1.487 growth factor 4.292 5.92E-16 2.16E-14 
E2F2 5.191 transcription 
regulator 
2.494 8.16E-16 2.95E-14 
EZH2 3.461 transcription 
regulator 
0.551 8.72E-16 3.14E-14 
NOTCH3 2.12 transcription 
regulator 
4.045 1.01E-15 3.60E-14 
IRF7 1.324 transcription 
regulator 
6.854 1.06E-15 3.73E-14 
RBL1 1.244 transcription 
regulator 
-4.344 4.95E-15 1.62E-13 
F2R 3.98 G-protein coupled 
receptor 
5.338 6.13E-15 2.00E-13 
BIRC5 4.835 other -1.709 1.25E-14 3.99E-13 
S100A9 3.908 other 3.047 1.42E-14 4.51E-13 
CD40 1.101 transmembrane 
receptor 
4.744 1.43E-14 4.51E-13 
NAMPT 2.502 cytokine 2.682 1.61E-14 5.07E-13 
MYBL2 6.787 transcription 
regulator 
2.79 2.89E-14 8.80E-13 
ABCB4 2.036 transporter -4.078 4.01E-14 1.18E-12 
JAG1 2.726 growth factor 4.426 7.45E-14 2.14E-12 
COL18A1 1.65 other -4.828 7.84E-14 2.22E-12 
PLK1 2.524 kinase -2.02 8.98E-14 2.51E-12 
ACVRL1 1.465 kinase -0.024 1.80E-13 4.82E-12 
S100A6 2.611 transporter 0.943 2.05E-13 5.45E-12 
CIP2A 1.493 other -1.763 2.76E-13 7.26E-12 
HOXA10 7.693 transcription 
regulator 
-2.33 2.84E-13 7.44E-12 
RARA 1.599 ligand-dependent 
nuclear receptor 
3.454 3.26E-13 8.42E-12 
TEAD4 2.789 transcription 
regulator 
4.204 3.84E-13 9.81E-12 
IL33 1.493 cytokine 5.613 4.17E-13 1.06E-11 
DCN 1.381 other -1.12 7.13E-13 1.77E-11 
S100A8 4.872 other 2.378 7.63E-13 1.89E-11 
ID3 2.405 transcription 
regulator 
-0.307 1.94E-12 4.46E-11 
BCL6 1.086 transcription 
regulator 
-1.729 4.74E-12 1.04E-10 
CCN1 2.124 other 3.663 7.29E-12 1.56E-10 
MYD88 1.788 other 6.715 1.37E-11 2.83E-10 
TREM1 4.669 transmembrane 
receptor 
3.236 2.24E-11 4.50E-10 
TNFSF13B 1.681 cytokine 3.489 2.32E-11 4.64E-10 
ENG 1.746 transmembrane 
receptor 
0.342 2.82E-11 5.59E-10 
HMOX1 2.464 enzyme -1.425 4.55E-11 8.73E-10 
TEAD2 3.281 transcription 
regulator 
4 7.47E-11 1.40E-09 
SPP1 1.055 cytokine 5.002 9.83E-11 1.79E-09 
IL10RA 1.235 transmembrane 
receptor 
-0.431 1.01E-10 1.84E-09 
SMAD1 1.086 transcription 
regulator 
3.773 1.03E-10 1.87E-09 
CXCR4 2.307 G-protein coupled 
receptor 
2.791 1.18E-10 2.12E-09 
ETS1 1.474 transcription 
regulator 
4.918 1.43E-10 2.55E-09 
NOX4 2.202 enzyme 3.208 2.56E-10 4.46E-09 
MAP3K1 1.417 kinase 4.376 2.69E-10 4.66E-09 
ATF3 1.086 transcription 
regulator 
-1.834 3.38E-10 5.79E-09 
THBS1 2.392 other 0.938 4.76E-10 8.00E-09 
WWTR1 2.559 transcription 
regulator 
2.275 5.97E-10 9.83E-09 
GLIS2 1.085 transcription 
regulator 
-3.45 6.95E-10 1.14E-08 
RUNX3 1.993 transcription 
regulator 
-3.767 8.63E-10 1.39E-08 
KLF6 1.287 transcription 
regulator 
1.665 9.32E-10 1.49E-08 
TFAP2A 3.639 transcription 
regulator 
-1.105 9.69E-10 1.54E-08 
PLAU 4.022 peptidase 2.262 1.38E-09 2.14E-08 
CHEK1 2.576 kinase 1.233 1.75E-09 2.67E-08 
PTGER4 1.554 G-protein coupled 
receptor 
-1.729 2.73E-09 4.06E-08 
ETV4 3.275 transcription 
regulator 
3.774 3.55E-09 5.16E-08 
S100A4 3.034 other 2.341 4.52E-09 6.43E-08 
MMP9 6.815 peptidase 3.108 5.04E-09 7.08E-08 
TLR3 1.497 transmembrane 
receptor 
5.937 5.38E-09 7.53E-08 
TEAD3 2.377 transcription 
regulator 
3.771 6.51E-09 9.03E-08 
SOX2 1.572 transcription 
regulator 
0.781 7.82E-09 1.07E-07 
TNFRSF1A 1.995 transmembrane 
receptor 
1.079 1.15E-08 1.52E-07 
ANXA2 3.997 other -1.574 1.25E-08 1.64E-07 
SNAI2 2.56 transcription 
regulator 
2.345 1.34E-08 1.75E-07 
HMGA1 1.256 transcription 
regulator 
1.163 1.44E-08 1.86E-07 
ITGA5 2.844 transmembrane 
receptor 
2.102 1.47E-08 1.90E-07 
PDGFC 1.867 growth factor 3.388 1.79E-08 2.30E-07 
TYROBP 1.505 transmembrane 
receptor 
2.2 2.24E-08 2.83E-07 
DLL4 1.581 other -0.357 2.27E-08 2.86E-07 
PRDM1 1.411 transcription 
regulator 
-1.626 2.51E-08 3.15E-07 
SPARC 2.132 other -0.419 2.68E-08 3.36E-07 
ZEB1 1.431 transcription 
regulator 
1.684 4.32E-08 5.24E-07 
NCF1 1.26 enzyme 2.905 5.57E-08 6.62E-07 
IGFBP2 4.882 other 2.823 6.06E-08 7.13E-07 
SOX4 2.495 transcription 
regulator 
3.934 6.18E-08 7.26E-07 
TIMP1 3.632 cytokine 1.604 1.11E-07 1.24E-06 
E2F5 1.566 transcription 
regulator 
2 1.15E-07 1.28E-06 
TLR2 1.287 transmembrane 
receptor 
1.861 1.60E-07 1.74E-06 
CXCL8 3.465 cytokine 2.976 2.01E-07 2.15E-06 
ASCL1 1.684 transcription 
regulator 
2.383 2.03E-07 2.16E-06 
PARP9 1.68 enzyme 2.373 2.29E-07 2.42E-06 
NEDD9 1.814 other 1.973 2.29E-07 2.42E-06 
ZMYND10 1.329 other -0.342 2.45E-07 2.55E-06 
ACKR3 1.907 G-protein coupled 
receptor 
2.027 2.45E-07 2.55E-06 
MSTN 1.995 growth factor 0.366 2.90E-07 2.98E-06 
SPHK1 1.69 kinase 1.646 3.16E-07 3.22E-06 
GMNN 1.505 transcription 
regulator 
-3.748 3.20E-07 3.26E-06 
WNT5A 1.846 cytokine 1.597 3.22E-07 3.27E-06 
CTSB 1.196 peptidase 2.408 3.31E-07 3.35E-06 
LGALS3 3.025 other 0.747 3.35E-07 3.39E-06 
BAX 1.466 transporter 2.256 3.61E-07 3.62E-06 
POSTN 6.219 other 2.589 3.61E-07 3.62E-06 
DDB2 1.301 other 0.354 5.65E-07 5.46E-06 
IFIH1 1.048 enzyme 3.142 6.04E-07 5.77E-06 
CDK2 2.938 kinase 2.496 7.22E-07 6.82E-06 
ACTL6A 1.54 other 0.905 8.51E-07 7.96E-06 
MAP3K14 1.231 kinase 2.881 8.79E-07 8.19E-06 
NFKB2 1.33 transcription 
regulator 
3.218 1.09E-06 1.01E-05 
RUNX1 1.627 transcription 
regulator 
1.428 1.10E-06 1.01E-05 
OSMR 2.989 transmembrane 
receptor 
1.4 1.13E-06 1.04E-05 
CASP3 1.189 peptidase 1.249 1.32E-06 1.20E-05 
GDF15 5.161 growth factor 0.765 1.48E-06 1.33E-05 
PGF 2.975 growth factor 2.245 1.66E-06 1.46E-05 
PLAUR 2.196 transmembrane 
receptor 
2.61 1.66E-06 1.46E-05 
MUC1 2.76 other 2.782 1.87E-06 1.63E-05 
BCL6B 1.668 transcription 
regulator 
1.309 1.87E-06 1.63E-05 
ADAMTS12 2.3 peptidase -3.138 1.88E-06 1.63E-05 
PTGS1 2.051 enzyme 1.5 2.30E-06 1.97E-05 
TRAF3IP2 1.532 other 3.939 2.71E-06 2.29E-05 
HSPB1 1.863 other 0.921 2.95E-06 2.47E-05 
PDGFRA 2.422 kinase 2.21 3.02E-06 2.51E-05 
TYMS 1.54 enzyme -2.213 3.10E-06 2.55E-05 
CEBPD 2.348 transcription 
regulator 
0.231 3.11E-06 2.56E-05 
ICAM1 2.224 transmembrane 
receptor 
3.418 3.40E-06 2.79E-05 
MEX3A 3.168 other 1.387 3.80E-06 3.09E-05 
MMP2 3.159 peptidase 2.053 3.80E-06 3.09E-05 
ADAM12 2.471 peptidase -0.269 4.19E-06 3.40E-05 
ANXA1 3.445 enzyme -1.1 4.31E-06 3.48E-05 
HLX 1.738 transcription 
regulator 
-1.66 4.31E-06 3.48E-05 
NT5E 1.606 phosphatase -1.134 5.34E-06 4.24E-05 
GPX1 1.407 enzyme -3.532 5.80E-06 4.59E-05 
IGFBP7 2.448 transporter -0.174 5.91E-06 4.64E-05 
EDNRA 2.101 transmembrane 
receptor 
2.828 5.91E-06 4.64E-05 
ETV1 2.044 transcription 
regulator 
2.158 6.60E-06 5.13E-05 
TGFB1I1 3.679 transcription 
regulator 
0.452 6.60E-06 5.13E-05 
SAMSN1 1.112 other 4.583 6.61E-06 5.13E-05 
CIITA 1.126 transcription 
regulator 
1.576 7.27E-06 5.59E-05 
LATS2 1.081 kinase 0.971 7.27E-06 5.59E-05 
PIM1 1.032 kinase 2.179 7.28E-06 5.60E-05 
AURKB 5.485 kinase -1.177 9.02E-06 6.78E-05 
IFI16 1.477 transcription 
regulator 
3.262 9.50E-06 7.12E-05 
KDR 1.413 kinase 1.105 1.02E-05 7.60E-05 
SHC1 1.751 other -0.967 1.60E-05 0.000115 
PSMB9 1.808 peptidase 0.391 1.67E-05 0.000118 
SERPINH1 3.581 other 2.401 1.67E-05 0.000118 
CPXM1 4.813 peptidase 2.236 1.74E-05 0.000121 
LEF1 1.707 transcription 
regulator 
1.929 1.90E-05 0.000132 
ZNF217 1.274 transcription 
regulator 
-1.846 2.03E-05 0.00014 
AIF1 1.007 other 2.607 2.16E-05 0.000149 
SPRY2 1.039 other -0.992 2.27E-05 0.000155 
ARHGAP31 1.041 other -0.905 2.81E-05 0.000189 
SOCS3 2.869 phosphatase -1.99 3.27E-05 0.000217 
TRIB3 2.785 kinase -1.897 3.29E-05 0.000218 
TNFAIP3 1.782 enzyme -2.028 3.63E-05 0.000237 
PLAT 2.471 peptidase 2.921 3.86E-05 0.000251 
AEBP1 2.812 peptidase -0.403 3.89E-05 0.000252 
CYBA 1.593 enzyme 2.414 3.89E-05 0.000252 
RUVBL1 1.297 transcription 
regulator 
1.808 3.92E-05 0.000252 
SNHG1 1.044 other -0.243 3.92E-05 0.000252 
LAMC1 2.891 other -2.616 4.03E-05 0.000256 
ID4 1.659 transcription 
regulator 
-1.951 4.03E-05 0.000256 
HOXA7 7.114 transcription 
regulator 
2.547 4.67E-05 0.000294 
C3AR1 1.143 G-protein coupled 
receptor 
2.107 5.03E-05 0.000317 
EPHA2 2.476 kinase 1.977 5.20E-05 0.000326 
NGFR 2.284 transmembrane 
receptor 
-0.328 5.22E-05 0.000326 
TNFRSF1B 1.187 transmembrane 
receptor 
3.29 5.64E-05 0.000348 
MCM7 1.516 enzyme NA 5.68E-05 0.000348 
CKS1B 1.363 kinase 2.215 5.68E-05 0.000348 
C3 1.272 peptidase 2.563 6.00E-05 0.000367 
C1QA 2.385 other 1.237 6.51E-05 0.000395 
CRNDE 2.876 other 2.37 6.99E-05 0.000424 
HAS2 3.55 enzyme 0.808 7.98E-05 0.000475 
CDK1 3.762 kinase 2.213 8.07E-05 0.000478 
RND3 2.011 enzyme 1.945 8.07E-05 0.000478 
LTBR 1.001 transmembrane 
receptor 
1.508 8.09E-05 0.000479 
MAPK7 1.248 kinase 1.631 8.83E-05 0.00052 
CLU 1.038 other 0.913 8.92E-05 0.000523 
HOXD10 8.605 transcription 
regulator 
1.343 9.14E-05 0.000534 
SOX11 3.377 transcription 
regulator 
1.646 9.89E-05 0.000575 
INHBB 1.78 growth factor 2.8 0.000108 0.000628 
EFNA2 1.755 kinase -2.673 0.000109 0.000628 
ID1 1.214 transcription 
regulator 
2.043 0.000109 0.00063 
MAFB 1.242 transcription 
regulator 
1.323 0.000115 0.000665 
COL1A1 4.721 other 1.934 0.000117 0.000667 
GAS2L3 3.14 other -2.63 0.000117 0.000667 
CBX3 1.288 transcription 
regulator 
NA 0.000121 0.000689 
PRKD1 1.199 kinase 3.532 0.000126 0.000714 
SMO 2.739 G-protein coupled 
receptor 
NA 0.000135 0.00076 
DES 2.527 other -1.98 0.000142 0.000789 
ELN 2.609 other 0.896 0.000149 0.000822 
CTSS 1.594 peptidase 1.026 0.000151 0.000834 
MEOX2 4.66 transcription 
regulator 
-2.474 0.000156 0.000859 
RIPK1 1.161 kinase 0.632 0.00018 0.000978 
MELK 5.434 kinase 1.896 0.000184 0.00098 
FZD7 2.772 G-protein coupled 
receptor 
1 0.000184 0.00098 
BRCA2 2.764 transcription 
regulator 
-1.154 0.000184 0.00098 
HELLS 1.894 enzyme 2 0.000185 0.00098 
NEDD4 1.549 enzyme -1.671 0.000185 0.00098 
PTTG1 3.247 transcription 
regulator 
-0.238 0.000215 0.00113 
STK40 1.112 kinase 1.589 0.000253 0.00131 
GAS5 1.03 other -1.604 0.000253 0.00131 
LOX 4.548 enzyme 1.906 0.000253 0.00131 
PDGFRB 1.307 kinase 0.842 0.000258 0.00133 
ITGB2 1.448 transmembrane 
receptor 
0.971 0.000278 0.00143 
EFNA4 1.655 kinase -3.317 0.00032 0.00161 
HEY1 1.792 transcription 
regulator 
-0.97 0.000354 0.00176 
GAPDH 1.067 enzyme -2.109 0.000355 0.00177 
DPP4 2.169 peptidase 0.283 0.000399 0.00198 
SULF2 1.281 enzyme 1.391 0.000415 0.00204 
ACTB 1.024 other 0.956 0.000415 0.00204 
BIRC3 1.523 enzyme -0.216 0.000484 0.00235 
USP18 1.777 peptidase -2.959 0.000487 0.00235 
MECOM 1.255 transcription 
regulator 
0.577 0.000487 0.00235 
CD14 2.631 transmembrane 
receptor 
3.24 0.000497 0.00236 
TIMP3 1.46 other -2.354 0.000507 0.0024 
MKI67 5.201 other 1.216 0.000516 0.00242 
PARP14 1.209 enzyme 1.387 0.000556 0.00257 
ITGA4 2.774 transmembrane 
receptor 
-0.129 0.000556 0.00257 
ATF5 1.443 transcription 
regulator 
1.969 0.000556 0.00257 
CISH 2.232 other -1.175 0.000598 0.00272 
CGAS 1.247 enzyme 2.815 0.000651 0.00294 
CDH2 1.052 other 0.577 0.000655 0.00294 
NRP1 2.015 transmembrane 
receptor 
0.128 0.000655 0.00294 
ADM 3.417 other -2.099 0.000735 0.00328 
MMP14 3.434 peptidase -1.195 0.000807 0.00359 
NLRC5 1.94 transcription 
regulator 
1.926 0.000832 0.00368 
PROCR 1.694 other 0.788 0.000862 0.0038 
BGN 1.918 other 0.239 0.000862 0.0038 
CALR 1.239 transcription 
regulator 
1.525 0.000902 0.00396 
CD36 1.975 transmembrane 
receptor 
4.202 0.000908 0.00398 
MCL1 1.314 transporter 0.871 0.000954 0.00414 
H1-2 2.235 other -0.42 0.000978 0.00423 
DNASE2 1.292 enzyme -2.784 0.00102 0.0044 
SOX9 1.516 transcription 
regulator 
2.165 0.00103 0.00444 
CCR1 1.03 G-protein coupled 
receptor 
0.895 0.00112 0.00476 
TMPO 1.043 other 2 0.00113 0.00476 
LGALS1 2.065 other 2.275 0.00138 0.00574 
TNFAIP6 1.941 other 1.915 0.00152 0.00624 
HNRNPAB 1.296 enzyme 2 0.00153 0.00624 
YBX1 1.7 transcription 
regulator 
1.719 0.00169 0.00687 
EBF1 1.316 transcription 
regulator 
3.057 0.00197 0.00772 
AURKA 2.84 kinase 1.023 0.00198 0.00772 
IGFBP5 2.229 other 2.007 0.00201 0.00778 
ACE 2.002 peptidase 0.816 0.00201 0.00778 
HOXA5 7.06 transcription 
regulator 
2.361 0.00201 0.00778 
HAND2 5.899 transcription 
regulator 
-0.444 0.00205 0.00795 
EFEMP1 2.47 enzyme -1.982 0.00212 0.00807 
TSPO 1.285 transmembrane 
receptor 
-1 0.00212 0.00807 
PLA2G5 2.165 enzyme 1.98 0.00212 0.00807 
NR5A2 4.148 ligand-dependent 
nuclear receptor 
0.978 0.00246 0.00929 
SOX6 1.243 transcription 
regulator 
0.862 0.0026 0.00976 
 
Upstream Regulator mean|logFC| Molecule Type Activation z-score P-value overlap BH p-value 
b. Upstream regulators for down-regulated DEGs 
TCF7L2 NA transcription 
regulator 
-9.736 9.79E-31 4.22E-27 
MAPT -1.398 other 0.728 2.66E-24 5.74E-21 
levodopa NA chemical - 
endogenous 
mammalian 
-3.748 2.00E-19 2.88E-16 
HTT NA transcription 
regulator 
1.919 7.36E-17 6.91E-14 
FMR1 NA translation regulator 5.211 8.02E-17 6.91E-14 
SNCA -4.209 enzyme -1.176 3.76E-15 2.52E-12 
REST NA transcription 
regulator 
4.284 4.09E-15 2.52E-12 
BDNF NA growth factor -5.649 6.51E-12 3.51E-09 
DSCAML1 -2.164 other -3.651 9.02E-12 4.32E-09 
HDAC4 NA transcription 
regulator 
-0.863 1.16E-10 4.98E-08 
DSCAM NA other -4.163 2.22E-10 8.70E-08 
MKNK1 NA kinase -5.477 3.02E-10 1.08E-07 
topotecan NA chemical drug 4.753 4.85E-10 1.50E-07 
CREB1 NA transcription 
regulator 
0.459 4.86E-10 1.50E-07 
PHF21A NA other -2.51 1.43E-09 4.12E-07 
MECP2 NA transcription 
regulator 
-2.411 6.96E-09 1.76E-06 
tetrodotoxin NA chemical drug 2.219 1.34E-08 3.21E-06 
Calmodulin NA group -2.059 1.87E-08 4.25E-06 
PSEN1 -1.141 peptidase -0.722 4.16E-08 8.96E-06 
GRIN3A NA ion channel 5.292 8.98E-08 1.84E-05 
DMD NA other -1.32 3.12E-07 6.11E-05 
APP -1.079 other 0.476 1.92E-06 0.000359 
NFASC -2.903 other -2.952 3.81E-06 0.000684 
tazemetostat NA chemical drug -2.929 4.89E-06 0.000842 
SLC30A3 NA transporter -2.433 1.96E-05 0.00325 
SP2509 NA chemical reagent -2.771 2.79E-05 0.00444 
MFSD2A NA transporter 2.949 2.89E-05 0.00444 




NA chemical reagent 0.152 4.39E-05 0.0061 
 
 
Supplementary Table 8. Number of common DEGs identified by the FIN method in both 
scenarios considered for TCGA-GBM data. On average about 94% of the DEGs obtained when 
randomly selected subset was considered were also found in DEGs identified using the full 
TCGA-GBM dataset. 
 
Scenario 2 Common DEGs Total # DEGs %common 
Selection 1 5339 5665 94.25 
Selection 2 5406 5697 94.89 
Selection 3 5308 5645 94.03 
Selection 4 5382 5710 94.26 
Selection 5 5358 5722 93.64 
Selection 6 5336 5743 92.91 
Selection 7 5382 5684 94.69 
Selection 8 5400 5797 93.15 
Selection 9 5352 5720 93.57 
Selection 10 5415 5698 95.03 
 
 
 
